{'fraction_non_alphanumeric': 0.04971002485501243, 'fraction_numerical': 0.04308202154101077, 'mean_word_length': 5.338582677165355, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The autologous hemopoietic stem cell transplantation in adult patients with lymphoma: Turkish Bone Marrow Transplantation Registry Results.

17517 Background: Turkish bone marrow transplantation registry (TBMTR) was established in 1995. Since 1992, data of adult lymphoma patients from fifteen transplant centers were collected and analyzed by TBMTR.


METHODS
A total of 437 adult lymphoma patients (185 Hodgkin's and 252 non-Hodgkin's lymphoma) undergoing autologous hemopoietic stem cell transplantation (HSCT) were registered by TBMTR from 1992 to 2002.


RESULTS
Peripheral blood was used in 94% of the transplantations as a source of stem cells. Non-TBI conditioning regimens were administered in 88% of the cases. The 100-day transplant related mortality was 11% in relapsed and in primary refractory Hodgkin's lymphoma patients; while transplant-related mortality (TRM) was found to be 9% and 30% in non-Hodgkin's lymphoma patients in first remission and in primary refractory cases, respectively. Infection was the most common cause of TRM. Overall (long-term) survival rates were 50% and 49% in relapsed cases and primary refractory cases with Hodgkin's lymphoma, respectively; while in non-Hodgkin's lymphoma patients the survival rates were 65% in cases in first remission, 50% in sensitive relapse, 0% in resistant relapse and 24% in primary refractory cases.


CONCLUSIONS
In conclusion, TBMTR results are comparable to EBMT and IBMTR results. Therefore, autologous HSCT may provide long-term survival in patients with Hodgkin's lymphoma as well as in patients with non-Hodgkin lymphoma in first remission and in sensitive relapse. Contributing authors and centers: F. Arpaci1, S. Ataergin1, G. Gurman2, S. Cagirgan3, M. Arat2, A. Ozet1, M. Ayli4, M. Ozcan2, A. Unal5, T. Soysal6, Y. Koc7, A. Buyukcelik8, A. Ozturk9, E. Ovali10, H. Goker11, B. Sahin12, S. Kalayoglu Besisik13, M. Bayik14, Z. Bolaman15, S. Bavbek16, M. Turan11GATA; 2Ankara University Hematology; 3Ege University; 4Numune Hospital, Ankara; 5Erciyes University; 6Cerrahpasa University; 7Hacettepe University Institute of Oncology; 8Ankara University Medical Oncology; 9GATA Haydarpasa; 10Karadeniz University; 11Hacettepe University; 12Cukurova University; 13Istanbul University Hematology; 14Marmara University; 15A.Menderes University; 16Istanbul University Institute of Oncology. No significant financial relationships to disclose.